New drug cocktail targets tough lung cancer mutation
NCT ID NCT06249282
First seen Apr 04, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This early-stage trial is testing whether combining two drugs, carfilzomib and sotorasib, is safe for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The study will involve 15 participants and aims to find the best dose and watch for side effects. If the combination proves safe, it could lead to a larger study to see if it helps shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
City of Hope at Irvine Lennar
RECRUITINGIrvine, California, 92618, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
carfilzomib and sotorasib
What this could lead to
If it works, this combination could offer a new treatment option for people with a specific type of advanced lung cancer that has stopped responding to other drugs.
What could go wrong
This is a very early, small phase I trial with only 15 people. It is mainly checking safety and dosing, not yet proving if the combination works. Side effects from the drugs could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.